Description: Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
Home Page: www.unicycive.com
UNCY Technical Analysis
4300 El Camino Real
Los Altos,
CA
94022
United States
Phone:
650 351 4495
Officers
| Name | Title |
|---|---|
| Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, CEO & Pres |
| Mr. John W. Townsend CPA | Chief Financial Officer |
| Dr. Pramod Gupta Ph.D. | Exec. VP of Pharmaceutical & Bus. Operations |
| Mr. Douglas Jermasek M.B.A. | Exec. VP of Corp. Strategy |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4394 |
| Price-to-Sales TTM: | 11.184 |
| IPO Date: | 2021-07-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |